U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06988319) titled 'Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study' on May 02.
Brief Summary: The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).
Study Start Date: Aug. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Chronic Pelvic Pain
Intervention:
DRUG: Psilocybin (Usona Institute)
Single do...